ExeVir Bio
PrivateLast Round
Grant
Jun 28, 2023
Total Funding Raised
$108.78M
Company Overview
ExeVir Bio is a biotechnology company that develops single-domain antibody-based therapies for the treatment and prevention of infectious diseases.
Sector
Healthcare & Life Sciences
Verticals
Biotechnology, Drug Discovery, Clinical Trials
Business Model
B2B
Customer Profile
Services & Consulting
AI Layer
Non-AI
Keywords
Historical Pricing
Historical view of private secondary pricing and transaction trends.
ExeVir Bio Comparables
Compare ExeVir Bio with similar companies based on industry and business-model similarity.
| Company | Similarity | Market Cap |
|---|---|---|
| DiosCURE Therapeutics SE | 89% | |
| Cerberus Therapeutics | 82% | |
| Invivyd | 79% |
ExeVir Bio Funding Rounds
Historical fundraising activity
| Round | Date | Amount Raised | Valuation | Investors | Sources |
|---|---|---|---|---|---|
| Grant | Jun 28, 2023 | ||||
| Debt | Dec 14, 2022 | ||||
| Grant | Jul 13, 2021 | ||||
| Series A | Mar 16, 2021 | ||||
| Series A | Jul 28, 2020 |
Key People
Founding team and executive leadership
ExeVir Bio Investors
Notable investors and investment history
| Investor | Rounds |
|---|---|
| UCB Ventures | Series A |
| Federal Holding and Investment Company | Series A |
| Sopartec | Series A |
| Noshaq | Series A |
| Fund+ | Series A |
| Société Régionale d'Investissement de Wallonie | Series A |
| UCB Ventures | Series A |
Market signals
Structured signals derived from secondary market and firmographic data.
- Jun 28, 2023
$1.74M grant received from VLAIO.
- Dec 14, 2022
$27M round from European Investment Bank Group.
ExeVir Bio Filings
Explore SEC and related filing metadata, where available.
| Type | Date | Amount Offered | Amount Sold | Filing | Pages | Download |
|---|
Filing documents are not displayed on this public page. Request access to learn about available coverage.
Request accessFrequently Asked Questions
Common questions about ExeVir Bio's valuation, stock price, and market status.
Is ExeVir Bio a public or private company?
ExeVir Bio is a private company.
What is the current stock price of ExeVir Bio?
ExeVir Bio is a private company with no public stock price. No recent secondary market data is available.
How much is ExeVir Bio worth (valuation)?
Valuation information for ExeVir Bio is not publicly available.
Can I buy ExeVir Bio stock?
ExeVir Bio shares may be available on secondary markets subject to transfer restrictions. Caplight facilitates secondary market transactions for accredited investors. Visit https://www.caplight.com to learn more.
When was ExeVir Bio's last funding round?
ExeVir Bio's most recent funding round was Grant on June 28, 2023.
Who are the main investors in ExeVir Bio?
Key investors in ExeVir Bio include Fund+.
Will ExeVir Bio IPO soon?
No public IPO plans have been announced for ExeVir Bio.
How can I track ExeVir Bio secondary market activity?
Caplight tracks bids, offers, and trades for private companies. Visit https://www.caplight.com to monitor ExeVir Bio's secondary market activity and sign up for updates.